Antiepileptic drug therapy in pregnancy II: Fetal and neonatal exposure

被引:21
作者
Hovinga, Collin A. [1 ,2 ]
Pennell, Page B. [3 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, LeBonheur Childrens Med Ctr, Dept Clin Pharm, Memphis, TN 38105 USA
[2] Univ Tennessee, Hlth Sci Ctr, LeBonheur Childrens Med Ctr, Dept Pediat, Memphis, TN 38105 USA
[3] Emory Univ, Sch Med, Emory Epilepsy Program, Atlanta, GA 30322 USA
来源
EPILEPSY IN WOMEN: THE SCIENTIFIC BASIS FOR CLINICAL MANAGEMENT | 2008年 / 83卷
关键词
D O I
10.1016/S0074-7742(08)00014-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The issue of how much an antiepileptic drug (AED) crosses the placenta and relative safety of lactation in mothers receiving AEDs are common clinical questions. Educating potential mothers with epilepsy regarding available information is warranted so that informed decisions and any needed neonatal monitoring is performed. Unfortunately, there is still limited data regarding the degree in which anticonvulsants cross the placenta and penetrate into breast milk. There is a greater appreciation of the factors that influence AED passive transfer across the placenta and into breast milk, as well as factors that ultimately influence neonatal AED distribution. In general, women with epilepsy can have healthy babies even with siginificant placental exposure and can breast-feed their babies safely with some cautions. Phenobarbital and primidone should be avoided in parents wishing to breast-feed. For the AEDs ethosuximide, levetiracetam, lamotrigine, topiramate, and zonisamide, there is a potential for significant breast milk concentrations; however, there are no firm guidelines on whether lactation is safe. In all cases, parents should be counseled to monitor their child for side effects and the need for routine monitoring.
引用
收藏
页码:241 / 258
页数:18
相关论文
共 68 条
[1]   Levetiracetam pharmacokinetics in neonates at birth [J].
Allegaert, K ;
Lewi, L ;
Naulaers, G ;
Lagae, L .
EPILEPSIA, 2006, 47 (06) :1068-1069
[2]  
American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776
[3]   Children versus adults: Pharmacokinetic and adverse-effect differences [J].
Anderson, GD .
EPILEPSIA, 2002, 43 :53-59
[4]   Antiepileptic medication during pregnancy: Does fetal genotype affect outcome? [J].
Atkinson, Diane E. ;
Brice-Bennett, Sophie ;
D'Souza, Stephen W. .
PEDIATRIC RESEARCH, 2007, 62 (02) :120-127
[5]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .2. PHENYTOIN, CARBAMAZEPINE, SULTHIAME, LAMOTRIGINE, VIGABATRIN, OXCARBAZEPINE AND FELBAMATE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (05) :341-369
[6]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .1. PHENOBARBITAL, PRIMIDONE, VALPROIC ACID, ETHOSUXIMIDE AND MESUXIMIDE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (04) :257-286
[7]   MODELING OF THE PASSAGE OF DRUGS INTO MILK [J].
BEGG, EJ ;
ATKINSON, HC .
PHARMACOLOGY & THERAPEUTICS, 1993, 59 (03) :301-310
[8]   PHARMACOKINETICS OF OXCARBAZEPINE AND 10-HYDROXY-CARBAZEPINE IN THE NEWBORN CHILD OF AN OXCARBAZEPINE-TREATED MOTHER [J].
BULAU, P ;
PAAR, WD ;
VONUNRUH, GE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (03) :311-313
[9]   Glucuronidation in humans - Pharmacogenetic and developmental aspects [J].
de Wildt, SN ;
Kearns, GL ;
Leeder, JS ;
van den Anker, JN .
CLINICAL PHARMACOKINETICS, 1999, 36 (06) :439-452
[10]  
FINCH E, 1954, J OBSTET GYN BRIT EM, V61, P833